Su 2005.

Methods	Allocation: Randomised Endpoint classification: Efficacy study Intervention model: Parallel assignment Masking: Double‐blind (participant, caregiver, investigator, outcomes assessor) Primary Purpose: treatment
Participants	Adults aged 18 ‐ 65 years meeting DSM‐IV criteria for MDD
Interventions	Intervention: DHA/EPA (1.6 ~ 2.8 g/d (5 capsules)) Comparator: placebo (5 g/d (5 capsules))
Outcomes	Primary: HDRS Secondary: BDI; Adverse events
Notes	No response from PI

BDI: Beck depression inventory
BNF: British National Formulary
CDI: Children's depression inventory
CGI: Clinical global impression
DHA: docosahexaenoic acid
DSM‐IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth edition
EPA: eicosapentaenoic acid
HDRS: Hamilton depression rating scale
MADRS: Montgomery‐Asberg Depression Rating Scale
MDD: major depressive disorder
MMSE: Mini‐Mental State Examination
SSRI: selective serotonin reuptake inhibiting